It has been a tough few months for India's Cadila Healthcare. After having two plants slapped by the FDA with a warning letter, the Indian drugmaker has now had a vaccines facility cuffed in a notice of concern by the World Health Organization (WHO) after it was found faking data about contamination issues at the facility.
Swiss-based Novartis has paid the U.S. SEC for $25 million to settle civil charges it bribed medical personnel in China to boost drug sales during the decade from 2003 to 2013, Reuters reports.
An effort to reassure investors after Taipei-based OBI Pharma posted disappointing clinical trial results on breast cancer candidate OBI-822/82 has apparently backfired for the head of Taiwan's lead science research agency after reports his daughter is a top shareholder.
Move over, Cosentyx--there's a new next-gen psoriasis med in town. On Tuesday, the FDA approved Eli Lilly's Taltz, the second IL-17A med to win its favor behind Novartis' contender.
Chinese leadership moved into high-gear to round up dozens of suspects linked to the illegal sale of vaccines in Shandong province, drawing in comment from the State Council and noting World Health Organization interest in the incident on the China FDA website.
India's Commerce Ministry has shot down claims by the U.S.-India Business Council that compulsory licenses for drugs are a thing of the past.
There aren't a lot of attractive options to treat nasal breathing disorders. Most are limited to unwieldy devices to aid breathing or surgical alteration of the nasal anatomy. Startup Aerin Medical hopes to offer a novel noninvasive approach--the use of nonablative radiofrequency energy to target and remodel nasal tissues to treat breathing orders caused by anatomical obstruction and mucosal dysfunction.
A hard look at cancer treatment options in Asia highlighted the gap in treatment pathways for innovative therapies in developing economies with much of the focus now on either screening or palliative care.
BioPharmaSpec is expanding its business into the potentially lucrative Asian market as new business development teams begin work in India and the Asia-Pacific region this month.
A mother-and-daughter team allegedly behind a massive illegal sale of vaccines in Shandong province are under arrest as China FDA moves to track down the potentially harmful supplies by calling for immediate help from manufacturers and distributors.